
Oncology NEWS International
- Oncology NEWS International Vol 15 No 12
- Volume 15
- Issue 12
Eisai Acquires Four Oncology- Related Products From Ligand
Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.
TEANECK, New JerseyEisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.
Articles in this issue
over 19 years ago
Best Rx Most Cost-Effective: RTOGover 19 years ago
Grape Seed Found to Be a Natural Aromatase Inhibitorover 19 years ago
Drug Combination Prevents ER-Negative Tumors in Miceover 19 years ago
Democrats' Agenda May Stifle Efforts for More Ca Fundingover 19 years ago
No Loss of Efficacy With Synchronous Chemotherapy/ESPover 19 years ago
'Share Care' Difficult for Ca Survivors and Their Oncologistsover 19 years ago
Biomarkers Panel Promising for Detecting Pancreatic Caover 19 years ago
Preop Avastin/Tarceva in RCCover 19 years ago
Reovirus Agent Shows Activity in Phase I TrialNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































